BioAsset

Insights / All articles

Research

$11 Insulin: California Rewrites the Prescription on Big Pharma

By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides

Starting January 1, 2026, California’s CalRx will offer long-acting insulin pens for about $11 each, or about $55 for a five-pack. With that move the state enters the drug supply chain as a manufacturer and brander, directly challenging the major insulin makers and their pricing models.

The insulin is a biosimilar to glargine, an insulin that has been chemically altered to last longer. It is produced through a partnership between CalRx, the nonprofit Civica Rx and the manufacturer Biocon Biologics.

The price gap

The U.S. average insulin price per standard unit was around $98.70 in 2018, accounting for all options. That compares with about $12 in Canada and under $10 in many other countries.

NIH data on average list prices show how U.S. prices have moved over time. Insulin from Eli Lilly (Humalog, Basaglar), Sanofi (Lantus) and Novo Nordisk (Levemir, Tresiba) climbed steeply from 1996 into the early 2020s, before the price cuts of 2024 brought list prices sharply back down. CalRx’s $11 pen, projected for 2026, comes in below all of them.

For patients, the average monthly insulin cost is $25 to $75 with insurance and $275 to $500 without. CalRx is a flat $11 per pen, insured or not.

What it means

For patients, this is a major win on cost and convenience. For legacy insulin manufacturers, it is a warning shot: their pricing models may face real structural competition.

About 3.6 million Californians have been diagnosed with diabetes. That figure includes type 2 diabetes, where other treatments may be used, and tens of thousands are already on insulin. The launch of $11 insulin under CalRx could affect hundreds of thousands of people.

A few things are worth watching:

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.